Clinuvel Pharmaceuticals
Logotype for Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals (CUV) investor relations material

Clinuvel Pharmaceuticals H1 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Clinuvel Pharmaceuticals Limited
H1 2026 earnings summary26 Feb, 2026

Executive summary

  • Revenue grew 4% year-over-year to $36.93 million for the half year ended 31 December 2025, marking a record first-half result and the 20th consecutive profitable period.

  • Profit after tax was $10.44 million, down 26% year-over-year, reflecting increased investment in R&D and business expansion.

  • Cash reserves rose 4% to $233 million, supporting self-funded growth, ongoing operations, and future initiatives.

  • The company remains debt-free for 21 years, with no equity dilution since 2016 and a self-financed expansion strategy.

  • EMA approved year-round SCENESSE® treatment for EPP, and an ADR Level II uplisting to Nasdaq is underway.

Financial highlights

  • Total expenses rose 22% to $25.98 million, mainly due to higher R&D, personnel, clinical, commercial, and corporate costs.

  • Interest income increased 14% to $5.3 million, driven by higher cash balances and favorable term deposit rates.

  • Other income saw a negative swing of $4.6 million due to unrealized FX translation losses.

  • Dividend of 5.0 cents per share fully franked was paid in September 2025.

  • Net assets increased to just under $250 million, with net tangible asset backing per ordinary security at $4.93.

Outlook and guidance

  • Sufficient funds to run programs through 2028, with continued investment in R&D, manufacturing, and commercial expansion.

  • Anticipates topline results for CUV105 vitiligo study and start of CUV107 in H2 2026, plus preclinical readout for new controlled-release formulation in H1 2026.

  • Uplisting to Nasdaq and expanded commercial activities planned, with higher second-half revenues expected due to seasonal demand.

  • Key regulatory milestones expected in 2026, including EMA engagement for adolescent EPP and Health Canada decision.

What drove the US to Europe revenue shift?
What is the VALLAURIX Centre's long-term goal?
Why did materials expenses increase 1,233%?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Clinuvel Pharmaceuticals earnings date

Logotype for Clinuvel Pharmaceuticals Limited
H2 202627 Aug, 2026
Clinuvel Pharmaceuticals
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Clinuvel Pharmaceuticals earnings date

Logotype for Clinuvel Pharmaceuticals Limited
H2 202627 Aug, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage